CLINICAL TRIALS PROFILE FOR PLENVU
✉ Email this page to a colleague
All Clinical Trials for PLENVU
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT03437265 ↗ | A Pharmacokinetic Study of PLENVU® in Healthy Subjects | Completed | Quotient Clinical | Phase 1 | 2020-09-03 | This study characterises the pharmacokinetic (PK) profile of the active ingredients of PLENVU (NER1006) and their related substances/metabolites. Subjects will receive PLENVU. |
| NCT03437265 ↗ | A Pharmacokinetic Study of PLENVU® in Healthy Subjects | Completed | Quotient Sciences | Phase 1 | 2020-09-03 | This study characterises the pharmacokinetic (PK) profile of the active ingredients of PLENVU (NER1006) and their related substances/metabolites. Subjects will receive PLENVU. |
| NCT03437265 ↗ | A Pharmacokinetic Study of PLENVU® in Healthy Subjects | Completed | Norgine | Phase 1 | 2020-09-03 | This study characterises the pharmacokinetic (PK) profile of the active ingredients of PLENVU (NER1006) and their related substances/metabolites. Subjects will receive PLENVU. |
| NCT03742232 ↗ | Study Comparing the Bowel Cleansing Efficacy of PLENVU® Versus SELG-ESSE® Using a 2-Day Split Dosing Regimen. | Completed | Istituto Clinico Humanitas | Phase 4 | 2018-10-31 | This study is a multicentre randomized parallel group phase IV study comparing the bowel cleansing efficacy, safety and tolerability of PLENVU® (a 1 litre PEG Bowel Cleansing Solution) versus SELG-ESSE® (a 4 litre PEG Bowel Cleansing Solution) using a 2-Day Split Dosing Regimen. |
| NCT04297423 ↗ | Two Low Volume Regimens for Colorectal Cancer Screening Colonoscopy | Recruiting | Casen Recordati S.L. | Phase 4 | 2020-03-11 | Colorectal cancer is the first neoplasm most commonly diagnosed in both sexes and the second leading cause of cancer death in Spain. Colorectal cancer screening Program in Barcelona was implanted in 2009 and approximately 1,500 colorectal cancer screening colonoscopies are performed annually at Hospital Clínic de Barcelona. Adequate colon preparation (anterograde cleansing with laxatives) improves polyp detection, decreases examination time, and complications. There are both low and high volume intestinal regimens with polyethylene glycol (PEG) as the main active ingredient or without it. Hypothesis: Two low volumen regimens, 1L PEG plus ascorbate and magnesium citrate plus picosulphate, at starting doses have the same Adenoma Detection Rate as cleansing solutions in preparation for screening colonoscopy. |
| NCT04297423 ↗ | Two Low Volume Regimens for Colorectal Cancer Screening Colonoscopy | Recruiting | Fundacion Clinic per a la Recerca Biomédica | Phase 4 | 2020-03-11 | Colorectal cancer is the first neoplasm most commonly diagnosed in both sexes and the second leading cause of cancer death in Spain. Colorectal cancer screening Program in Barcelona was implanted in 2009 and approximately 1,500 colorectal cancer screening colonoscopies are performed annually at Hospital Clínic de Barcelona. Adequate colon preparation (anterograde cleansing with laxatives) improves polyp detection, decreases examination time, and complications. There are both low and high volume intestinal regimens with polyethylene glycol (PEG) as the main active ingredient or without it. Hypothesis: Two low volumen regimens, 1L PEG plus ascorbate and magnesium citrate plus picosulphate, at starting doses have the same Adenoma Detection Rate as cleansing solutions in preparation for screening colonoscopy. |
| NCT04297423 ↗ | Two Low Volume Regimens for Colorectal Cancer Screening Colonoscopy | Recruiting | Hospital Clinic of Barcelona | Phase 4 | 2020-03-11 | Colorectal cancer is the first neoplasm most commonly diagnosed in both sexes and the second leading cause of cancer death in Spain. Colorectal cancer screening Program in Barcelona was implanted in 2009 and approximately 1,500 colorectal cancer screening colonoscopies are performed annually at Hospital Clínic de Barcelona. Adequate colon preparation (anterograde cleansing with laxatives) improves polyp detection, decreases examination time, and complications. There are both low and high volume intestinal regimens with polyethylene glycol (PEG) as the main active ingredient or without it. Hypothesis: Two low volumen regimens, 1L PEG plus ascorbate and magnesium citrate plus picosulphate, at starting doses have the same Adenoma Detection Rate as cleansing solutions in preparation for screening colonoscopy. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for PLENVU
Condition Name
Clinical Trial Locations for PLENVU
Clinical Trial Progress for PLENVU
Clinical Trial Phase
Clinical Trial Sponsors for PLENVU
Sponsor Name
